Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.38 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.38 |
| ▸ | PDE1A | P54750 | 1/20 | 0.38 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.38 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.38 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.37 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SHBG | P04278 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL874467 | 0.78 | CA1 (0.44) | LTB4RLTB4R2FKBP1A | |
| SCHEMBL9340622 | 0.72 | SMN1; SMN2 (0.51) | GLANPSR1SMN1; SMN2 | |
| SCHEMBL9341094 | 0.71 | GLA (0.43) | GLANPSR1SMN1; SMN2 | |
| SCHEMBL874390 | 0.69 | GLA (0.48) | GLANPSR1SMN1; SMN2TLR9POLB | |
| SCHEMBL27669794 | 0.69 | SMN1; SMN2 (0.55) | SMN1; SMN2PDE1BFKBP1A | |
| SCHEMBL3948980 | 0.69 | SMN1; SMN2 (0.55) | SMN1; SMN2PDE1BFKBP1A | |
| SCHEMBL24128714 | 0.68 | CHRM2 (0.45) | — | |
| SCHEMBL16766174 | 0.67 | SMN1; SMN2 (0.42) | GLANPSR1SMN1; SMN2 | |
| SCHEMBL24881281 | 0.67 | SMN1; SMN2 (0.42) | GLANPSR1SMN1; SMN2 | |
| SCHEMBL16766175 | 0.67 | SMN1; SMN2 (0.42) | GLANPSR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120083501-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. | 2012-04-05 | — | — | US | disclosed |
| WO-2012040641-A2 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. (US) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083501-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | BACE1, PSEN1, PSEN2 | GLA 122/4885NPSR1 1591/4885SMN1; SMN2 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.